Market Access of Biosimilars in the EU - Value Assessment/HTA?
Termindetails
Wann
von 18:00 bis 20:30
Wo
Kontakttelefon
Teilnehmer
Especially those who are responsible for the international business will benefit from this meeting.
Aims and objectives:
Biosimilars are playing an increasingly important role in the national healthcare systems of the EU. But market access and reimbursement are facing challenges:
- Is there a consensus regarding whether or not HTA assessment is necessary for biosimilars?
- How can a substitution be regulated and potentially also be enforced?
These and further topics will be addressed in an intensive discussion among experts from five national HTA bodies.
Topics:
- Market access for biosimilars in Germany - the current challenges and regulatory trends at a glance
- Market access for biosimilars in the UK, France, Germany, Spain/Catalonia and Denmark
- Current discussion: Value assessment for biosimilars foreseen? Substitution regulated?